Epiminder

Epiminder is at the forefront of biotechnology research, dedicated to revolutionizing epilepsy care. With a focus on continuous insights and uninterrupted life for patients, Epiminder is making significant strides in the field of neurological health. The company's innovative approach addresses the challenges faced by over 50 million people globally affected by epilepsy, particularly those who do not respond to traditional medication.

Epiminder is transforming epilepsy management with its implantable continuous EEG monitoring (iCEM®) system, the Minder® system. Having secured authorization through the FDA's de novo pathway, Minder is establishing a robust commercial presence in the US market. The Minder system offers a breakthrough by providing continuous and objective EEG data, essential for a comprehensive understanding of a patient's condition. This data-driven approach empowers clinicians to make informed decisions, leading to more effective and personalized treatment strategies.

Headquartered in Melbourne, Australia, and with a significant office in Dallas, TX, USA, Epiminder is committed to advancing neurological health through cutting-edge technology. Epiminder's system represents a major advancement in epilepsy care, akin to implantable cardiac monitors and continuous glucose monitors used in other conditions requiring continuous physiological signal monitoring.

We invite the management of Epiminder to enhance your company's visibility by creating a customized and exclusive company showcase and product listing on our platform.